Table 3.
Hematologic adverse events | Number of subjects (N) | Number of studies (k) | I2 | Fixed effect | 95% CI | Random effect | 95% CI |
---|---|---|---|---|---|---|---|
Adverse event (overall) | |||||||
Anemia | 1,058 | 12 | 98.4 | 0.653 | 0.624–0.681 | 0.546 | 0.299–0.782 |
Neutropenia | 1,058 | 12 | 97.6 | 0.513 | 0.483–0.543 | 0.46 | 0.273–0.654 |
Thrombocytopenia | 1,037 | 11 | 96.8 | 0.298 | 0.271–0.326 | 0.255 | 0.125–0.412 |
Febrile neutropenia | 815 | 8 | 70.4 | 0.06 | 0.045–0.078 | 0.066 | 0.033–0.110 |
Adverse event (grade 3–4) | |||||||
Neutropenia | 1,521 | 18 | 94.3 | 0.264 | 0.242–0.286 | 0.246 | 0.165–0.338 |
Anemia | 1,222 | 15 | 86.5 | 0.115 | 0.098–0.133 | 0.102 | 0.059–0.154 |
Febrile neutropenia | 995 | 12 | 38.6 | 0.055 | 0.042–0.070 | 0.054 | 0.035–0.076 |
Thrombocytopenia | 1,073 | 11 | 69.6 | 0.032 | 0.022–0.043 | 0.03 | 0.013–0.054 |
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.